NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved

Stock Information for Scinai Immunotherapeutics Ltd Sponsed ADR (New)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Scinai Immunotherapeutics Ltd Sponsed ADR (New)

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
BiondVax Reports Second Quarter Financial Results and Provides Business Update
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
BiondVax to Present at BIO-Europe Spring

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.